Use of Synthetic Peptides Anti-Idiotypes for Controlling Human Immunodeficiency Virus Infection
Abstract
We are examining the correlation between the presence of antibodies in sera which recognize synthetic peptides whose sequences correspond to the principal neutralizing determinant of HIV-1 and the ability of these sera to neutralize homologous HIV-1 isolates in vitro. Sera from infected individuals from the United States and Tanzania were examined. Our data indicates that there is no strong correlation between the presence of anti-V3 antibodies in human sera and viral neutralizing activity. In addition, in composite peptide representing conserved regions within the V3 loop of HIV-1 gp 120 has been produced and is currently being used to generate monoclonal and polyclonal anti- peptide antibodies in mice and rabbits, respectively. These antibodies are being tested for their ability to recognize, and neutralize a panel of HIV-1 isolates. Recent reports indicate, that regional isolates of HIV-1 may be present throughout the world. Differences in epidemiologic patterns suggest that these, isolates may differ in their levels of virulence. We are therefore isolating primary HIV-l isolates from infected individuals from the United States and Tanzania. We currently have 12 primary isolates from the United States and 2 from Tanzania. These HIV-1 isolates will be tested for differences in cell culture characteristics as well iis for phenotypic differences. Human Immunodeficiency Virus, Synthetic peptides, Geographically diverse populations, Chimpanzees, RAI, Antibodies
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 31, 1992
- Accession Number
- ADA269558
Entities
People
- Ronald C. Kennedy
Organizations
- Texas Biomedical Research Institute